GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » 3-Year FCF Growth Rate

Biomark Diagnostics (Biomark Diagnostics) 3-Year FCF Growth Rate

: -22.40% (As of Dec. 2023)
View and export this data going back to 2015. Start your Free Trial

Biomark Diagnostics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -22.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -11.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Biomark Diagnostics was 32.90% per year. The lowest was -58.70% per year. And the median was -8.50% per year.


Competitive Comparison

For the Diagnostics & Research subindustry, Biomark Diagnostics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics 3-Year FCF Growth Rate Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's 3-Year FCF Growth Rate falls into.



Biomark Diagnostics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Biomark Diagnostics  (OTCPK:BMKDF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Biomark Diagnostics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics (Biomark Diagnostics) Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines